The secondary endpoint was the combined endpoint of death or hospitalization of any cause within 3 months.
Outcome parameters were all-cause mortality and a combined endpoint of death and rehospitalisation for congestive heart failure.
Even though copeptin has been shown to predict adverse outcome in various diseases [46, 47], there was only a trend for the association with the combined endpoint of death or hospitalization in this study after adjusting for all other relevant risk factors.
Prior comparisons of these risk scores in NSTEMI and cardiac chest pain patients have cited the greater discriminative capacity of the GRACE scores in-hospital and at 1 year for mortality alone, a composite endpoint of death and recurrent MI, and the combined triple endpoint of death, recurrent MI, and recurrent revascularization [8], [9], [10].
Our observations are comparable to those of prior studies that have reported modest c-statistics for the TIMI UA/NSTEMI score despite using a combined endpoint of death and recurrent MI (C = 0.59 at 1-month [17], and C = 0.585 [8] or 0.62 [17] at 1-year).
aCombined endpoint of death or thrombotic event.
Events were defined by a combined endpoint of death (all causes), myocardial infarction (MI) and stroke.
The primary outcome was a composite endpoint of death or severe complications.
Relative risks were larger for the endpoint of death (see supplementary table 2).
Thirty women had poor outcome as predefined using a combined endpoint of death, EF and FC.
Figure 3b depicts the receiver operator curve for the endpoint of death.
